Filing Flows › Janux Therapeutics (JANX) › Q3 2026
Janux Therapeutics (JANX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Janux Therapeutics (JANX) reported revenue of $9.3M for the third quarter 2026 (Q3 2026), -7% from a year earlier and -10% from the quarter before. Operating margin was -336.5%, net loss $21.6M (232.2% of revenue).
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.3M | -10% | -7% |
| Operating profit | −$31.3M | — | — |
| Net earnings | −$21.6M | — | — |
| Operating cash flow | −$25.2M | -302% | — |
What changed
Revenue was $9.3M in Q3 2026, down 7% year over year and down 10% from the previous quarter.
Operating costs exceeded revenue by $31.3M, an operating margin of -336.5%. Total costs fell 10% while revenue fell 7%. The quarter ended with a net loss of $21.6M, narrower than the previous quarter's $22.0M loss. Non-operating items added $9.7M, -45% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$25.2M. Non-cash charges added back $458K of depreciation and $8.5M of share-based compensation. Working capital and other items used $12.6M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$25.2M.
Questions
What was Janux Therapeutics' revenue in the third quarter 2026?
Janux Therapeutics (JANX) reported revenue of $9.3M for the third quarter 2026 (Q3 2026), -7% from a year earlier and -10% from the quarter before.
Was Janux Therapeutics profitable in the third quarter 2026?
Operating loss was $31.3M (-336.5% of revenue) and net loss $21.6M.
Source: Janux Therapeutics 10-Q on SEC EDGAR.